Alnylam Pharmace. buy Royal Bank of Canada
Summary
This prediction ended on 13.09.24 with a price of €235.90. The BUY prediction by Royal_Bank_of_Canada finished with a performance of 20.97%. Royal_Bank_of_Canada has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Royal_Bank_of_Canada has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -0.244% | -0.244% | 43.443% |
iShares Core DAX® | -1.471% | 1.895% | 25.178% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Current prediction by Royal_Bank_of_Canada for Alnylam Pharmace.
Stopped prediction by Royal_Bank_of_Canada for Alnylam Pharmace.
Alnylam Pharmace.
28.08.23
28.08.24
29.08.24
Alnylam Pharmace.
18.08.23
18.08.24
19.08.24
Alnylam Pharmace.
04.08.23
04.08.24
05.08.24
Alnylam Pharmace.
25.07.23
25.07.24
26.07.24